Header Logo

Connection

SRDAN VERSTOVSEK to Survivors

Back to Details
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Survivors.
SRDAN VERSTOVSEK
Connection Strength
0.069
Survivors
  1. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.
    View in: PubMed
    Score: 0.069
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.